Home/Pipeline/KESONOTIDE™

KESONOTIDE™

Broad chronic inflammatory diseases

PreclinicalActive

Key Facts

Indication

Broad chronic inflammatory diseases

Phase

Preclinical

Status

Active

Company

About Filamon

Australian‑focused biotech creating multi‑modal anti‑inflammatory drugs for age‑related chronic diseases.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Neurology Ophthalmology Immunology